

## Lisa Kasiewicz

---

**From:** Lisa Kasiewicz  
**Sent:** Thursday, March 2, 2023 12:43 PM  
**To:** Lisa Kasiewicz  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

I also give my permission.

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>, Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto<sup>1</sup>**, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

**From:** Lisa Kasiewicz  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C  
**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, Yuri Matsumoto<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



**Lisa Kasiewicz, PhD**  
Associate Principal Scientist, Formulation

**O:** (617) 603-0070 **M:** (203) 673-9730

**E:** [lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601 | Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

CONFIDENTIALITY NOTICE: The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

## Lisa Kasiewicz

---

**From:** Souvik Biswas  
**Sent:** Wednesday, March 1, 2023 4:14 PM  
**To:** Lisa Kasiewicz; Aaron Beach; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Christopher Cheng; Sara Garcia; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Padma Malyala; Kallanthottathil Rajeev; Andrew Bellinger; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

**As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.**

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Regards,  
Souvik

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C  
**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>, Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto<sup>1</sup>**, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

## Lisa Kasiewicz

---

**From:** Aaron Beach  
**Sent:** Wednesday, March 1, 2023 4:42 PM  
**To:** Lisa Kasiewicz; Souvik Biswas; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Christopher Cheng; Sara Garcia; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Padma Malyala; Kallanthottathil Rajeev; Andrew Bellinger; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** RE: REPLY REQUESTED: Author change for GalNac Manuscript NCOMMS-22-08508C

**As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.**

**GalNac-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**



**Aaron Beach (he/his)**  
Senior Director – Internal Quality Control

**O:** (937) 287-6157 **M:** (937) 287-6157  
**E:** [abeach@vervetx.com](mailto:abeach@vervetx.com)  
**A:** 201 Brookline Avenue, Suite 601, Boston, MA 02215  
[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cductta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNac Manuscript NCOMMS-22-08508C  
**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

## **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>, Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



**Lisa Kasiewicz, PhD**  
Associate Principal Scientist, Formulation

**O:** (617) 603-0070 **M:** (203) 673-9730

**E:** [lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601| Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

## Lisa Kasiewicz

---

**From:** Huilan Ren  
**Sent:** Wednesday, March 1, 2023 3:11 PM  
**To:** Lisa Kasiewicz  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Hi Lisa,

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Best,  
Huilan

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C  
**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,  
Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa

## Lisa Kasiewicz

---

**From:** Chaitali Dutta  
**Sent:** Wednesday, March 1, 2023 4:29 PM  
**To:** Lisa Kasiewicz  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

**As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.**

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Regards,  
Chaitali

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C  
**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,  
Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto<sup>1</sup>**, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa

## Lisa Kasiewicz

---

**From:** Anne Marie Mazzola  
**Sent:** Wednesday, March 1, 2023 3:10 PM  
**To:** Lisa Kasiewicz  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

**As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.**

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>

**Sent:** Wednesday, March 1, 2023 3:09 PM

**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>

**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



## Lisa Kasiewicz

---

**From:** Ellen Rohde  
**Sent:** Wednesday, March 1, 2023 8:50 PM  
**To:** Lisa Kasiewicz  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Hi Lisa,

**As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.**  
Ellen Rohde

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C  
**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**"As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below."**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,  
Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa

## Lisa Kasiewicz

---

**From:** Alexandra Chadwick  
**Sent:** Wednesday, March 1, 2023 4:54 PM  
**To:** Lisa Kasiewicz  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Alexandra Chadwick

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Date:** Wednesday, March 1, 2023 at 3:08 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>, Aaron Beach <abeach@vervetx.com>, Huilan Ren <hren@vervetx.com>, Chaitali Dutta <cdutta@vervetx.com>, Anne Marie Mazzola <ammazzola@vervetx.com>, Ellen Rohde <erohde@vervetx.com>, Alexandra Chadwick <achadwick@vervetx.com>, Christopher Cheng <ccheng@vervetx.com>, Sara Garcia <sgarcia@vervetx.com>, Amit Khera <akhera@vervetx.com>, Kiran Musunuru <kmusunuru@vervetx.com>, Sekar Kathiresan <skathiresan@vervetx.com>, Padma Malyala <pmalyala@vervetx.com>, Kallanthottathil Rajeev <krajeev@vervetx.com>, Andrew Bellinger <abellinger@vervetx.com>, sowmyai@bu.edu <sowmyai@bu.edu>, Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto<sup>1</sup>**, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa

## Lisa Kasiewicz

---

**From:** Christopher Cheng  
**Sent:** Wednesday, March 1, 2023 7:15 PM  
**To:** Andrew Bellinger; Lisa Kasiewicz; Souvik Biswas; Aaron Beach; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Sara Garcia; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Padma Malyala; Kallanthottathil Rajeev; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Christopher Cheng

---

**From:** Andrew Bellinger <abellinger@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 6:59 PM  
**To:** Lisa Kasiewicz <lkasiewicz@vervetx.com>; Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; sowmyai@bu.edu <sowmyai@bu.edu>; Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Andrew Bellinger

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Date:** Wednesday, March 1, 2023 at 3:08 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>, Aaron Beach <abeach@vervetx.com>, Huilan Ren <hren@vervetx.com>, Chaitali Dutta <cdutta@vervetx.com>, Anne Marie Mazzola <ammazzola@vervetx.com>, Ellen Rohde <erohde@vervetx.com>, Alexandra Chadwick <achadwick@vervetx.com>, Christopher Cheng <ccheng@vervetx.com>, Sara Garcia <sgarcia@vervetx.com>, Amit Khera <akhera@vervetx.com>, Kiran Musunuru <kmusunuru@vervetx.com>, Sekar Kathiresan <skathiresan@vervetx.com>, Padma Malyala <pmalyala@vervetx.com>, Kallanthottathil Rajeev <krajeev@vervetx.com>, Andrew Bellinger <abellinger@vervetx.com>, sowmyai@bu.edu <sowmyai@bu.edu>, Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



**Lisa Kasiewicz, PhD**  
Associate Principal Scientist, Formulation

**O:** (617) 603-0070 **M:** (203) 673-9730

**E:** [lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601| Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

## Lisa Kasiewicz

---

**From:** Sara Garcia  
**Sent:** Wednesday, March 1, 2023 4:47 PM  
**To:** Aaron Beach; Lisa Kasiewicz; Souvik Biswas; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Christopher Cheng; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Padma Malyala; Kallanthottathil Rajeev; Andrew Bellinger; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Sara Garcia

**From:** Aaron Beach <abeach@vervetx.com>  
**Date:** Wednesday, March 1, 2023 at 4:42 PM  
**To:** Lisa Kasiewicz <lkasiewicz@vervetx.com>, Souvik Biswas <sbiswas@vervetx.com>, Huilan Ren <hren@vervetx.com>, Chaitali Dutta <cdutta@vervetx.com>, Anne Marie Mazzola <ammazzola@vervetx.com>, Ellen Rohde <erohde@vervetx.com>, Alexandra Chadwick <achadwick@vervetx.com>, Christopher Cheng <ccheng@vervetx.com>, Sara Garcia <sgarcia@vervetx.com>, Amit Khera <akhera@vervetx.com>, Kiran Musunuru <kmusunuru@vervetx.com>, Sekar Kathiresan <skathiresan@vervetx.com>, Padma Malyala <pmalyala@vervetx.com>, Kallanthottathil Rajeev <krajeev@vervetx.com>, Andrew Bellinger <abellinger@vervetx.com>, sowmyai@bu.edu <sowmyai@bu.edu>, Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**



**Aaron Beach (he/his)**

Senior Director – Internal Quality Control

**O:** (937) 287-6157 **M:** (937) 287-6157

**E:** [abeach@vervetx.com](mailto:abeach@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601, Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>;

Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu; Yuri Matsumoto <yumatsumoto@vervetx.com>

**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

**Importance:** High

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>, Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto<sup>1</sup>**, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



**Lisa Kasiewicz, PhD**  
Associate Principal Scientist, Formulation

**O:** (617) 603-0070 **M:** (203) 673-9730

**E:** [lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601| Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

## Lisa Kasiewicz

---

**From:** Sowmya Iyer <sowmyai@bu.edu>  
**Sent:** Wednesday, March 1, 2023 3:38 PM  
**To:** Lisa Kasiewicz  
**Cc:** Aaron Beach; Alexandra Chadwick; Amit Khera; Andrew Bellinger; Anne Marie Mazzola; Chaitali Dutta; Christopher Cheng; Ellen Rohde; Huilan Ren; Kallanthottathil Rajeev; Kiran Musunuru; Padma Malyala; Sara Garcia; Sekar Kathiresan; Souvik Biswas; Yuri Matsumoto  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Thanks,  
Sowmya Iyer

On Wed, Mar 1, 2023 at 3:09 PM Lisa Kasiewicz <[lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)> wrote:

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,

## Lisa Kasiewicz

---

**From:** Amit Khera  
**Sent:** Wednesday, March 1, 2023 3:09 PM  
**To:** Lisa Kasiewicz  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Date:** Wednesday, March 1, 2023 at 3:08 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>, Aaron Beach <abeach@vervetx.com>, Huilan Ren <hren@vervetx.com>, Chaitali Dutta <cdutta@vervetx.com>, Anne Marie Mazzola <ammazzola@vervetx.com>, Ellen Rohde <erohde@vervetx.com>, Alexandra Chadwick <achadwick@vervetx.com>, Christopher Cheng <ccheng@vervetx.com>, Sara Garcia <sgarcia@vervetx.com>, Amit Khera <akhera@vervetx.com>, Kiran Musunuru <kmusunuru@vervetx.com>, Sekar Kathiresan <skathiresan@vervetx.com>, Padma Malyala <pmalyala@vervetx.com>, Kallanthottathil Rajeev <krajeev@vervetx.com>, Andrew Bellinger <abellinger@vervetx.com>, sowmyai@bu.edu <sowmyai@bu.edu>, Yuri Matsumoto <ymatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



## Lisa Kasiewicz

---

**From:** Kiran Musunuru  
**Sent:** Wednesday, March 1, 2023 7:59 PM  
**To:** Lisa Kasiewicz  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Kiran Musunuru

CONFIDENTIALITY NOTICE: The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

---

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Sent:** Wednesday, March 1, 2023 3:08 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>; Aaron Beach <abeach@vervetx.com>; Huilan Ren <hren@vervetx.com>; Chaitali Dutta <cdutta@vervetx.com>; Anne Marie Mazzola <ammazzola@vervetx.com>; Ellen Rohde <erohde@vervetx.com>; Alexandra Chadwick <achadwick@vervetx.com>; Christopher Cheng <ccheng@vervetx.com>; Sara Garcia <sgarcia@vervetx.com>; Amit Khera <akhera@vervetx.com>; Kiran Musunuru <kmusunuru@vervetx.com>; Sekar Kathiresan <skathiresan@vervetx.com>; Padma Malyala <pmalyala@vervetx.com>; Kallanthottathil Rajeev <krajeev@vervetx.com>; Andrew Bellinger <abellinger@vervetx.com>; sowmyai@bu.edu <sowmyai@bu.edu>; Yuri Matsumoto <yamatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,  
Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa

## Lisa Kasiewicz

---

**From:** Sekar Kathiresan  
**Sent:** Thursday, March 2, 2023 6:58 AM  
**To:** Lisa Kasiewicz  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Lisa,

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Best,  
Sek



Sekar Kathiresan, MD  
Chief Executive Officer

M: (617) 584-6343  
E: [skathiresan@vervetx.com](mailto:skathiresan@vervetx.com)  
A: 201 Brookline Avenue, 6<sup>th</sup> Floor | Boston, MA 02215  
[www.vervetx.com](http://www.vervetx.com)

Learn more @nytimes here: [A 'Cure for Heart Disease'? A Single Shot Succeeds in Monkeys](#)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

**From:** Lisa Kasiewicz <[lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)>  
**Date:** Wednesday, March 1, 2023 at 3:08 PM  
**To:** Souvik Biswas <[sbiswas@vervetx.com](mailto:sbiswas@vervetx.com)>, Aaron Beach <[abeach@vervetx.com](mailto:abeach@vervetx.com)>, Huilan Ren <[hren@vervetx.com](mailto:hren@vervetx.com)>, Chaitali Dutta <[cdutta@vervetx.com](mailto:cdutta@vervetx.com)>, Anne Marie Mazzola <[ammazzola@vervetx.com](mailto:ammazzola@vervetx.com)>, Ellen Rohde <[erohde@vervetx.com](mailto:erohde@vervetx.com)>, Alexandra Chadwick <[achadwick@vervetx.com](mailto:achadwick@vervetx.com)>, Christopher Cheng <[ccheng@vervetx.com](mailto:ccheng@vervetx.com)>, Sara Garcia <[sgarcia@vervetx.com](mailto:sgarcia@vervetx.com)>, Amit Khera <[akhera@vervetx.com](mailto:akhera@vervetx.com)>, Kiran Musunuru <[kmusunuru@vervetx.com](mailto:kmusunuru@vervetx.com)>, Sekar Kathiresan <[skathiresan@vervetx.com](mailto:skathiresan@vervetx.com)>, Padma Malyala <[pmalyala@vervetx.com](mailto:pmalyala@vervetx.com)>, Kallanthottathill Rajeev <[krajeev@vervetx.com](mailto:krajeev@vervetx.com)>, Andrew Bellinger <[abellinger@vervetx.com](mailto:abellinger@vervetx.com)>, "sowmyai@bu.edu" <[sowmyai@bu.edu](mailto:sowmyai@bu.edu)>, Yuri Matsumoto <[ymatsumoto@vervetx.com](mailto:yamatsumoto@vervetx.com)>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>, Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto<sup>1</sup>**, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



**Lisa Kasiewicz, PhD**  
Associate Principal Scientist, Formulation

**O:** (617) 603-0070 **M:** (203) 673-9730

**E:** [lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601| Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

## Lisa Kasiewicz

---

**From:** Padma Malyala  
**Sent:** Thursday, March 2, 2023 10:18 AM  
**To:** Lisa Kasiewicz; Souvik Biswas; Aaron Beach; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Christopher Cheng; Sara Garcia; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Kallanthottathil Rajeev; Andrew Bellinger; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** RE: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Hi,

**As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below."**

Updated byline is below.

### **GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Warm Regards,  
Padma

Padma Malyala  
Vice President, Formulation & Analytical Development

#### **Verve Therapeutics**

**O:** (617) 603-0070 **M:** (857) 208-3848

**E:** [pmalyala@vervetx.com](mailto:pmalyala@vervetx.com)

**A:** 201 Brookline Avenue, 6<sup>th</sup> Floor | Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

CONFIDENTIALITY NOTICE: The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

**From:** Lisa Kasiewicz <[lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)>

**Sent:** Wednesday, March 1, 2023 3:09 PM

**To:** Souvik Biswas <[sbiswas@vervetx.com](mailto:sbiswas@vervetx.com)>; Aaron Beach <[abeach@vervetx.com](mailto:abeach@vervetx.com)>; Huilan Ren <[hren@vervetx.com](mailto:hren@vervetx.com)>; Chaitali Dutta <[cductta@vervetx.com](mailto:cductta@vervetx.com)>; Anne Marie Mazzola <[ammazzola@vervetx.com](mailto:ammazzola@vervetx.com)>; Ellen Rohde <[erohde@vervetx.com](mailto:erohde@vervetx.com)>; Alexandra Chadwick <[achadwick@vervetx.com](mailto:achadwick@vervetx.com)>; Christopher Cheng <[ccheng@vervetx.com](mailto:ccheng@vervetx.com)>; Sara Garcia <[sgarcia@vervetx.com](mailto:sgarcia@vervetx.com)>; Amit Khera <[akhera@vervetx.com](mailto:akhera@vervetx.com)>; Kiran Musunuru <[kmusunuru@vervetx.com](mailto:kmusunuru@vervetx.com)>; Sekar Kathiresan <[skathiresan@vervetx.com](mailto:skathiresan@vervetx.com)>; Padma Malyala <[pmalyala@vervetx.com](mailto:pmalyala@vervetx.com)>; Kallanthottathil Rajeev <[krajeev@vervetx.com](mailto:krajeev@vervetx.com)>; Andrew Bellinger <[abellinger@vervetx.com](mailto:abellinger@vervetx.com)>; sowmyai@bu.edu; Yuri Matsumoto

## Lisa Kasiewicz

---

**From:** Kallanthottathil Rajeev  
**Sent:** Wednesday, March 1, 2023 4:37 PM  
**To:** Lisa Kasiewicz; Souvik Biswas; Aaron Beach; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Christopher Cheng; Sara Garcia; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Padma Malyala; Andrew Bellinger; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.  
Rajeev



**Kallanthottathil Rajeev (Rajeev)**

Vice President, CMC

**O:** (617) 603-0070 **M:** (617) 331-7618

**E:** [krajeev@vervetx.com](mailto:krajeev@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601, Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

**From:** Lisa Kasiewicz <[lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)>

**Date:** Wednesday, March 1, 2023 at 3:08 PM

**To:** Souvik Biswas <[sbiswas@vervetx.com](mailto:sbiswas@vervetx.com)>, Aaron Beach <[abeach@vervetx.com](mailto:abeach@vervetx.com)>, Huilan Ren <[hren@vervetx.com](mailto:hren@vervetx.com)>, Chaitali Dutta <[cdutta@vervetx.com](mailto:cdutta@vervetx.com)>, Anne Marie Mazzola <[ammazzola@vervetx.com](mailto:ammazzola@vervetx.com)>, Ellen Rohde <[erohde@vervetx.com](mailto:erohde@vervetx.com)>, Alexandra Chadwick <[achadwick@vervetx.com](mailto:achadwick@vervetx.com)>, Christopher Cheng <[ccheng@vervetx.com](mailto:ccheng@vervetx.com)>, Sara Garcia <[sgarcia@vervetx.com](mailto:sgarcia@vervetx.com)>, Amit Khera <[akhera@vervetx.com](mailto:akhera@vervetx.com)>, Kiran Musunuru <[kmusunuru@vervetx.com](mailto:kmusunuru@vervetx.com)>, Sekar Kathiresan <[skathiresan@vervetx.com](mailto:skathiresan@vervetx.com)>, Padma Malyala <[pmalyala@vervetx.com](mailto:pmalyala@vervetx.com)>, Kallanthottathil Rajeev <[krajeev@vervetx.com](mailto:krajeev@vervetx.com)>, Andrew Bellinger <[abellinger@vervetx.com](mailto:abellinger@vervetx.com)>, sowmyai@bu.edu <[sowmyai@bu.edu](mailto:sowmyai@bu.edu)>, Yuri Matsumoto <[ymatsumoto@vervetx.com](mailto:yumatsumoto@vervetx.com)>

**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**"As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below."**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>,

Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa



**Lisa Kasiewicz, PhD**  
Associate Principal Scientist, Formulation

**O:** (617) 603-0070 **M:** (203) 673-9730

**E:** [lkasiewicz@vervetx.com](mailto:lkasiewicz@vervetx.com)

**A:** 201 Brookline Avenue, Suite 601| Boston, MA 02215

[www.vervetx.com](http://www.vervetx.com)

**CONFIDENTIALITY NOTICE:** The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

## Lisa Kasiewicz

---

**From:** Andrew Bellinger  
**Sent:** Wednesday, March 1, 2023 6:59 PM  
**To:** Lisa Kasiewicz; Souvik Biswas; Aaron Beach; Huilan Ren; Chaitali Dutta; Anne Marie Mazzola; Ellen Rohde; Alexandra Chadwick; Christopher Cheng; Sara Garcia; Amit Khera; Kiran Musunuru; Sekar Kathiresan; Padma Malyala; Kallanthottathil Rajeev; sowmyai@bu.edu; Yuri Matsumoto  
**Subject:** Re: REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.

Andrew Bellinger

**From:** Lisa Kasiewicz <lkasiewicz@vervetx.com>  
**Date:** Wednesday, March 1, 2023 at 3:08 PM  
**To:** Souvik Biswas <sbiswas@vervetx.com>, Aaron Beach <abeach@vervetx.com>, Huilan Ren <hren@vervetx.com>, Chaitali Dutta <cdutta@vervetx.com>, Anne Marie Mazzola <ammazzola@vervetx.com>, Ellen Rohde <erohde@vervetx.com>, Alexandra Chadwick <achadwick@vervetx.com>, Christopher Cheng <ccheng@vervetx.com>, Sara Garcia <sgarcia@vervetx.com>, Amit Khera <akhera@vervetx.com>, Kiran Musunuru <kmusunuru@vervetx.com>, Sekar Kathiresan <skathiresan@vervetx.com>, Padma Malyala <pmalyala@vervetx.com>, Kallanthottathil Rajeev <krajeev@vervetx.com>, Andrew Bellinger <abellinger@vervetx.com>, sowmyai@bu.edu <sowmyai@bu.edu>, Yuri Matsumoto <yumatsumoto@vervetx.com>  
**Subject:** REPLY REQUESTED: Author change for GalNAc Manuscript NCOMMS-22-08508C

Dear Team:

*Nature Communications* requires all-author approval when the author list is changed. Dr. Yuri Matsumoto was mistakenly left off of the authors list and will thus be added as a correction. I will be collating these responses and providing them to *Nature Communications*.

Can you please each reply to this e-mail with the statement:

**“As a coauthor of this manuscript, I agree with the addition of Dr. Yuri Matsumoto to the author list as outlined below.”**

Updated byline is below.

**GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy**

Lisa N. Kasiewicz<sup>1</sup>, Souvik Biswas<sup>1</sup>, Aaron Beach<sup>1</sup>, Huilan Ren<sup>1</sup>, Chaitali Dutta<sup>1</sup>, Anne Marie Mazzola<sup>1</sup>, Ellen Rohde<sup>1</sup>, Alexandra Chadwick<sup>1</sup>, Christopher Cheng<sup>1</sup>, Sara P. Garcia<sup>1</sup>, Sowmya Iyer<sup>1</sup>, **Yuri Matsumoto**<sup>1</sup>, Amit V. Khera<sup>1</sup>, Kiran Musunuru<sup>2</sup>, Sekar Kathiresan<sup>1</sup>, Padma Malyala<sup>1</sup>, Kallanthottathil G. Rajeev<sup>1</sup>, and Andrew M. Bellinger<sup>1\*</sup>

Thank you very much for your assistance,  
Lisa